 
Biography
        Eunice Machuka has over 15 years of national and international experience in biomedical research; She is interested in underpinning host-pathogen interaction mechanisms for i) epidemiological surveillance and preparedness and ii) improved productivity and adaptability. Her PhD research focused on variations among local and exotic Kenyan pig hosts and their responses when challenged with varying doses of the African swine fever virus (ASFV). Previously at the Medical Research Council Unit, The Gambia, at the London School of Hygiene and Tropical Medicine, she worked on pneumonia aetiology projects that informed HiB and pneumococcal vaccine use and efficacy. At the International Livestock Research Institute (ILRI), Kenya, she works on assorted viruses, namely, Peste des petits ruminants virus (PPRV), African swine Fever, Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). She is actively undertaking genomics characterisation of the PPRV and MERS-CoV for epidemiological purposes while participating in projects that test vaccine development against African swine fever (ASF). She is currently a Postdoctoral Research Fellow at the College of Veterinary Medicine at Kansas State University, working on Rift Valley Fever Virus transmission blocking studies.
  Research interests
        Host-pathogen interaction dynamics, Diagnostics sndf Biotechbology
  Projects you're working on
        ECo-PPR Project - characterisation of Peste des petits ruminants virus (PPRV) in small ruminants; African swine Fever inactivated vaccine safety; Rift valley fever virus (RVFV) transmission blocking study  Discipline
        Bioinformatics      Challenge study design      Clinical trials – safety      Epidemiology      Molecular biology      Virology  Host species
        Camels      Cattle      Pigs      Small ruminants      Wildlife      Zoonoses  Pathogen
        Viruses      Viruses›African swine fever virus      Viruses›Respiratory syncytial virus      Viruses›Rift Valley fever virus  Stage of vaccine development
        Adjuvants      Pre-clinical trials